Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gain Therapeutics Inc (NQ: GANX )

2.320 -0.180 (-7.20%)
Streaming Delayed Price Updated: 2:02 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gain Therapeutics Inc

< Previous 1 2 3 Next >
Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate at Upcoming Investor Conferences
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
Data demonstrates improvement in cognitive function in GBA1 Parkinson’s disease model in addition to reversal of motor function deficits 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Gain Therapeutics Inc. (NASDAQ: GANX) Releases Pricing of Underwritten Public Offering, Projected to Reach $11M
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Proposed Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024
New data demonstrating improvement of cognitive performance after treatment with GT-02287 in preclinical model of GBA1 Parkinson’s disease 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Present at Public Ventures Discovery Day
Gain Therapeutics’ Former CEO and current Board Member Eric Richman to participate in fireside chat hosted by Public Ventures President Lou Basenese and Aberdeen Investment Management President Jeb... 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
Data support the ability of GT-02287 to prevent several steps in the disease cascade resulting from GCase misfolding and dysfunction 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
Event, moderated by Hartaj Singh and Eka Gigauri of Oppenheimer & Co., will be held on Thursday, February 22, 2024 at 11:00 am EST 
From Gain Therapeutics, Inc.
Via GlobeNewswire
UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
Data presented at 20th WORLDSymposium™ show progressive reversal of motor deficit and corresponding reduction of neurodegeneration biomarker NfL to level of control arm 
From Gain Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.